Effects of Teprenone Modified Quadruple Therapy on Hp Virulence Gene and HGF/c-Met Signaling Pathway
Objective:To investigate the efficacy of Teprenone modified quadruple therapy in the treatment of Helicobacter pylori(Hp)positive chronic atrophic gastritis(CAG)and its effect on the expression of Hp virulence genes and serum hepatocyte growth factor/hepatocyte growth factor receptor(HGF/c-Met)signaling pathway.Method:A total of 114 patients with Hp positive CAG admitted to the Second Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from July 2021 to June 2023 were selected as the research objects,they were randomly divided into control group(n=57)and observation group(n=57).The control group was treated with conventional bismuth quadruple therapy,and the observation group was treated with Teprenone modified quadruple therapy.The efficacy,Hp eradication rate,Hp recurrence rate,adverse reactions,Hp virulence factors[cytotoxin-associated protein(CagA),vacuolated cytotoxin(VacA)],serum HGF and gastric mucosal HGF,c-Met expression levels were observed in the two groups.Result:The total effective rate and eradication rate of Hp in the observation group were higher than those in the control group,and the recurrence rate of Hp was lower than that in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the positive rates of Hp virulence factors CagA and VacA in the observation group were lower than those in the control group(P<0.05).After treatment,the expression levels of HGF in serum and HGF and c-Met in gastric mucosa in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Teprenone modified quadruple therapy in the treatment of Hp positive CAG patients can significantly reduce the positive rates of CagA and VacA and the expression levels of HGF and c-Met,and has better efficacy than bismuth quadruple therapy without increasing safety risks.
万方数据
维普
